2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Standardized Data Collection for Cardiovascular Trials Initiative (SCTI), Karen A. Hicks, Kenneth W. Mahaffey, Roxana Mehran, Steven Nissen, Stephen D. Wiviott, Billy Dunn, Scott D. Solomon, John R. Marler, John R. Teerlink, Andrew Farb, David A. Morrow, Shari L. Targum, Cathy A. Sila, Mary T. Thanh Hai, Michael R. Jaff, Hylton V. Joffe, Donald E. Cutlip, Akshay S. Desai, Eldrin F. Lewis & 31 others C. Michael Gibson, Martin J. Landray, A. Michael Lincoff, Christopher J. White, Steven S. Brooks, Kenneth Rosenfield, Michael J. Domanski, Alexandra J. Lansky, John J.V. McMurray, James E. Tcheng, Steven R. Steinhubl, Paul Burton, Laura Mauri, Christopher M. O'Connor, Marc A. Pfeffer, H. M.James Hung, Norman L. Stockbridge, Bernard R. Chaitman, Robert J. Temple, Heather D. Fitter, Kachikwu Illoh, Kenneth J. Cavanaugh, Benjamin M. Scirica, Ilan Irony, Rachel E. Brown Kichline, Jonathan G. Levine, Anna Park, Leonard Sacks, Ana Szarfman, Ellis F. Unger, Lori Ann Wachter

Research output: Contribution to journalReview article

  • 4 Citations

Abstract

This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

LanguageEnglish (US)
Pages1021-1034
Number of pages14
JournalJournal of the American College of Cardiology
Volume71
Issue number9
DOIs
StatePublished - Mar 6 2018

Fingerprint

United States Food and Drug Administration
Myocardial Infarction
Clinical Trials
Marketing
Meta-Analysis
Safety
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • cardiovascular and stroke endpoint definitions
  • cardiovascular and stroke outcome definitions
  • cardiovascular and stroke outcomes
  • cardiovascular endpoint definitions
  • cardiovascular endpoints
  • cardiovascular outcomes
  • clinical trial endpoint definitions
  • clinical trial endpoints
  • endpoint definitions
  • endpoints
  • outcome definitions
  • stroke endpoint definitions
  • stroke endpoints
  • stroke outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. / Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

In: Journal of the American College of Cardiology, Vol. 71, No. 9, 06.03.2018, p. 1021-1034.

Research output: Contribution to journalReview article

Standardized Data Collection for Cardiovascular Trials Initiative (SCTI) 2018, '2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials' Journal of the American College of Cardiology, vol. 71, no. 9, pp. 1021-1034. https://doi.org/10.1016/j.jacc.2017.12.048
Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology. 2018 Mar 6;71(9):1021-1034. https://doi.org/10.1016/j.jacc.2017.12.048
Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). / 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. In: Journal of the American College of Cardiology. 2018 ; Vol. 71, No. 9. pp. 1021-1034.
@article{6d08621addb64b7bb68adf4c027606ef,
title = "2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials",
abstract = "This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.",
keywords = "cardiovascular and stroke endpoint definitions, cardiovascular and stroke outcome definitions, cardiovascular and stroke outcomes, cardiovascular endpoint definitions, cardiovascular endpoints, cardiovascular outcomes, clinical trial endpoint definitions, clinical trial endpoints, endpoint definitions, endpoints, outcome definitions, stroke endpoint definitions, stroke endpoints, stroke outcomes",
author = "{Standardized Data Collection for Cardiovascular Trials Initiative (SCTI)} and Hicks, {Karen A.} and Mahaffey, {Kenneth W.} and Roxana Mehran and Steven Nissen and Wiviott, {Stephen D.} and Billy Dunn and Solomon, {Scott D.} and Marler, {John R.} and Teerlink, {John R.} and Andrew Farb and Morrow, {David A.} and Targum, {Shari L.} and Sila, {Cathy A.} and {Thanh Hai}, {Mary T.} and Jaff, {Michael R.} and Joffe, {Hylton V.} and Cutlip, {Donald E.} and Desai, {Akshay S.} and Lewis, {Eldrin F.} and Gibson, {C. Michael} and Landray, {Martin J.} and Lincoff, {A. Michael} and White, {Christopher J.} and Brooks, {Steven S.} and Kenneth Rosenfield and Domanski, {Michael J.} and Lansky, {Alexandra J.} and McMurray, {John J.V.} and Tcheng, {James E.} and Steinhubl, {Steven R.} and Paul Burton and Laura Mauri and O'Connor, {Christopher M.} and Pfeffer, {Marc A.} and Hung, {H. M.James} and Stockbridge, {Norman L.} and Chaitman, {Bernard R.} and Temple, {Robert J.} and Fitter, {Heather D.} and Kachikwu Illoh and Cavanaugh, {Kenneth J.} and Scirica, {Benjamin M.} and Ilan Irony and {Brown Kichline}, {Rachel E.} and Levine, {Jonathan G.} and Anna Park and Leonard Sacks and Ana Szarfman and Unger, {Ellis F.} and Wachter, {Lori Ann}",
year = "2018",
month = "3",
day = "6",
doi = "10.1016/j.jacc.2017.12.048",
language = "English (US)",
volume = "71",
pages = "1021--1034",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

AU - Standardized Data Collection for Cardiovascular Trials Initiative (SCTI)

AU - Hicks, Karen A.

AU - Mahaffey, Kenneth W.

AU - Mehran, Roxana

AU - Nissen, Steven

AU - Wiviott, Stephen D.

AU - Dunn, Billy

AU - Solomon, Scott D.

AU - Marler, John R.

AU - Teerlink, John R.

AU - Farb, Andrew

AU - Morrow, David A.

AU - Targum, Shari L.

AU - Sila, Cathy A.

AU - Thanh Hai, Mary T.

AU - Jaff, Michael R.

AU - Joffe, Hylton V.

AU - Cutlip, Donald E.

AU - Desai, Akshay S.

AU - Lewis, Eldrin F.

AU - Gibson, C. Michael

AU - Landray, Martin J.

AU - Lincoff, A. Michael

AU - White, Christopher J.

AU - Brooks, Steven S.

AU - Rosenfield, Kenneth

AU - Domanski, Michael J.

AU - Lansky, Alexandra J.

AU - McMurray, John J.V.

AU - Tcheng, James E.

AU - Steinhubl, Steven R.

AU - Burton, Paul

AU - Mauri, Laura

AU - O'Connor, Christopher M.

AU - Pfeffer, Marc A.

AU - Hung, H. M.James

AU - Stockbridge, Norman L.

AU - Chaitman, Bernard R.

AU - Temple, Robert J.

AU - Fitter, Heather D.

AU - Illoh, Kachikwu

AU - Cavanaugh, Kenneth J.

AU - Scirica, Benjamin M.

AU - Irony, Ilan

AU - Brown Kichline, Rachel E.

AU - Levine, Jonathan G.

AU - Park, Anna

AU - Sacks, Leonard

AU - Szarfman, Ana

AU - Unger, Ellis F.

AU - Wachter, Lori Ann

PY - 2018/3/6

Y1 - 2018/3/6

N2 - This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

AB - This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

KW - cardiovascular and stroke endpoint definitions

KW - cardiovascular and stroke outcome definitions

KW - cardiovascular and stroke outcomes

KW - cardiovascular endpoint definitions

KW - cardiovascular endpoints

KW - cardiovascular outcomes

KW - clinical trial endpoint definitions

KW - clinical trial endpoints

KW - endpoint definitions

KW - endpoints

KW - outcome definitions

KW - stroke endpoint definitions

KW - stroke endpoints

KW - stroke outcomes

UR - http://www.scopus.com/inward/record.url?scp=85044846776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044846776&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2017.12.048

DO - 10.1016/j.jacc.2017.12.048

M3 - Review article

VL - 71

SP - 1021

EP - 1034

JO - Journal of the American College of Cardiology

T2 - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -